Aptorum Group Ltd announced a merger with DiamiR Biosciences Corp on July 14, 2025, where DiamiR will become a wholly owned subsidiary, with existing shareholders owning approximately 70% and 30% of the new entity respectively. This significant event emphasizes the consolidation of operations to facilitate advancements in neurodegenerative disease diagnostics.